COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02254265
Recruitment Status : Completed
First Posted : October 1, 2014
Results First Posted : December 14, 2018
Last Update Posted : May 14, 2019
Information provided by (Responsible Party):
Sun Pharma Global FZE

Brief Summary:
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).

Condition or disease Intervention/treatment Phase
Keratoconjunctivitis Sicca Dry Eye Disease Drug: OTX-101 0.05% Drug: OTX-101 0.09% Drug: Vehicle Phase 2 Phase 3

Detailed Description:

Keratoconjunctivitis sicca (KCS) is a common multifactorial ophthalmologic disorder of the tears and ocular surface characterized by symptoms of burning, stinging, itching, grittiness, scratchiness, foreign body sensation, dryness, stickiness and tired eye sensation.

This study is the first clinical safety and efficacy study with OTX-101 and is designed to compare two dose concentrations of OTX-101 against vehicle (placebo) in reducing the signs and symptoms of KCS and evaluate safety when dosed twice a day in both eyes over an 84 day period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 455 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-Masked, Vehicle-Controlled, Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Study Start Date : September 2014
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Diseases

Arm Intervention/treatment
Experimental: OTX-101 0.05%
OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
Drug: OTX-101 0.05%
OTX-101 0.05% Ophthalmic Solution

Experimental: OTX-101 0.09%
OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
Drug: OTX-101 0.09%
OTX-101 0.09% Ophthalmic Solution

Placebo Comparator: Vehicle
Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
Drug: Vehicle
Vehicle of OTX-101 Ophthalmic Solution

Primary Outcome Measures :
  1. Conjunctival Staining [ Time Frame: Baseline to 84 days ]

    Mean change from baseline at day 84 for the lissamine green conjunctival staining score in the designated study eye.

    The Investigator recorded a score for each area of each eye on a 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots) scale

  2. Global Symptom Score [ Time Frame: Baseline to 84 days ]

    Mean change from baseline at day 84 for the global symptom score.

    The freuency and severy of dry eye and irritation scores were used to calculate symptom score as follows:

    Frequency of dry eye/irritation based on a scale of 0 (rarely) to 100 (all the time) Severity of dryness or irritation based on a scale of 0 (very mildly) to 100 (very severe).

    The global symptom score was calculated as the square root of the frequency score times the severity score

Secondary Outcome Measures :
  1. Tear Film Break up Time (TBUT) [ Time Frame: Baseline to 84 days ]
    Mean change from baseline in TBUT in the study eye from baseline at Day 84

  2. Corneal Staining Score [ Time Frame: Baseline to 84 days ]
    Mean Change from Baseline in Corneal Staining Score in the Study Eye. Expanded National Eye Institute Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale

  3. Schirmer's Test [ Time Frame: Baseline to 84 days ]

    Change from Baseline in Categorized Schirmer's Test Score. Schirmer's test was performed with strips placed in both eyes at the same time. Strips were removed after 5 minutes and the amount of wetting (in mm) was recorded as scores from 1 to 5.

    1: < 3 mm, 3 - 6 mm, 7 - 10 mm, 11 - 14 mm, and 5: > 14 mm

  4. Patient Satisfaction [ Time Frame: Baseline to 84 days ]
    Patient satisfaction with treatment score using 5-point scale (1=extremely dissatisfied to 5=extremely satisfied)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects age 18 years or older on the date of informed consent.
  2. All subjects must provide signed written consent prior to participation in any study-related procedures.
  3. Patient-reported history of KCS for a period of at least 6 months.
  4. Clinical diagnosis of bilateral KCS supported by OTX-101-2014-001 study assessments.
  5. Lissamine green conjunctival staining sum score of ≥ 3 to ≤ 9 out of a total possible score of 12 (scoring excludes superior zones 2 and 4) in the same eye at Screening and Baseline.
  6. Global symptom score ≥ 40 at both Screening and Baseline.
  7. Corrected Snellen VA of better than 20/200 in each eye.
  8. Willing to discontinue use of current dry eye therapy (including artificial tears or ocular lubricants) during the study as of the run-in period.
  9. Female subjects of childbearing potential must have a negative urine pregnancy test at Screening. Women of childbearing potential (ie, women who are not either postmenopausal for one year or surgically sterile) must use an acceptable form of contraception throughout the study.

Exclusion Criteria:

  1. Use of cyclosporine ophthalmic emulsion 0.05% (Restasis®) within 3 months prior to Screening.
  2. Previous treatment failure (lack of efficacy) on cyclosporine ophthalmic emulsion 0.05% (Restasis).
  3. Diagnosed with Sjögren's disease ˃5 years prior to Screening.
  4. Clinical diagnosis of seasonal and perennial allergic conjunctivitis.
  5. Use of systemic and topical medications that are known to cause dry eye within 7 days prior to Screening and throughout the study period. These include the following medications:

    • Immunomodulators (permitted if dose is stable for 3 months prior to screening and does not change during the study period)
    • Antihistamines (including over-the counter (OTC))
    • Cholinergics
    • Antimuscarinics
    • Tricyclic antidepressants
    • Phenothiazines
    • Retinoids
  6. Oral omega-3 fatty acids (permitted if dose is stable for 3 months prior to Screening and does not change during the study period)
  7. Use of any topical ophthalmic medications, prescription (including antiglaucoma medications) or OTC (including artificial tears), other than the assigned study medication during the study period.
  8. Current active eye disease other than KCS (i.e., any disease for which topical or systemic ophthalmic medication is necessary).
  9. History of herpes keratitis.
  10. Unstable macular disease (e.g., age-related macular degeneration, diabetic maculopathy). Stable macular disease is defined as no reduction in central VA within 6 months prior to Screening.
  11. Diagnosis of chronic uveitis.
  12. Corneal transplant (e.g., penetrating keratoplasty, lamellar keratoplasty, Descemet's stripping endothelial keratoplasty (DSEK) ).
  13. Corneal refractive surgery (e.g., laser-assisted in situ keratomileusis (LASIK]) photo refractive keratectomy (PRK), limbal relaxing incision (LRI) ) within 6 months prior to screening or postoperative refractive surgery symptoms of dryness that have not resolved.
  14. Cataract surgery within 3 months prior to Screening.
  15. Non-laser glaucoma surgery at any time; glaucoma laser procedures within 3 months prior to Screening.
  16. Presence of punctal plugs or past history of permanent punctal occlusion (e.g., cautery).
  17. Lagophthalmos or clinically significant eyelid margin irregularity of the study eye whether congenital or acquired.
  18. Presence of conjunctivochalasis (i.e., mechanical blockage of the lower lid punctum by redundant conjunctiva).
  19. Presence of pterygium in the study eye.
  20. Unwilling to discontinue use of contact lenses during the duration of the study.
  21. Preplanned elective surgery or hospitalization during the study period.
  22. HIV-positive.
  23. Unable to reliably report symptoms and history.
  24. Has known hypersensitivity or contraindication to the study medication(s) or their components.
  25. Has a history or presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the result(s) of the study.
  26. Has a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up.
  27. Women who are pregnant or breastfeeding.
  28. Participation in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.
  29. Previous randomization into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02254265

Layout table for location information
United States, Ohio
Cleveland, Ohio, United States
Sponsors and Collaborators
Sun Pharma Global FZE
Layout table for additonal information
Responsible Party: Sun Pharma Global FZE Identifier: NCT02254265    
Other Study ID Numbers: OTX-101-2014-001
First Posted: October 1, 2014    Key Record Dates
Results First Posted: December 14, 2018
Last Update Posted: May 14, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Eye Diseases
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Conjunctival Diseases
Corneal Diseases
Lacrimal Apparatus Diseases